Literature DB >> 27061063

Serum Tyrosine-to-Phenylalanine Ratio is Low in Parkinson's Disease.

Masaaki Hirayama1, Makoto Tsunoda2, Mitsutoshi Yamamoto3, Takao Tsuda4, Kinji Ohno5.   

Abstract

BACKGROUND: Noninvasive biomarkers for Parkinson's disease (PD) are currently unavailable.
OBJECTIVE: To search for a biomarker unique to PD in sweat and serum.
METHODS: Sweat samples in 42 PD patients and 16 controls were analyzed using liquid chromatography/mass spectrometry (LC/MS). The principal component analysis (PCA) and the orthogonal projections to latent structures (OPLS) analysis were employed. Serum Phe and Tyr levels were determined using the HPLC-fluorescence detection system in 28 de novo PD patients, 52 L-Dopa-treated PD patients, and 27 controls.
RESULTS: PCA and OPLS analyses of LC/MS of sweat samples revealed that Tyr, Phe, Leu (Ile), and Asp have high effect sizes to differentiate PD and controls. As Phe and Tyr are precursors of dopamine, we quantified the serum Phe and Tyr levels in de novo and treated PD patients, as well as in controls. Phe was high in de novo patients, but not in treated patients. In contrast, Tyr tended to be low in treated patients, but not in de novo patients. Tyr/Phe ratios were lower in both de novo and treated patients than in controls. The Tyr/Phe ratios were all higher than 0.82 in controls, whereas 49% of the de novo and treated patients had Tyr/Phe ratios less than 0.82. The low Tyr/Phe ratios were associated with male patients and low doses of entacapone. However, Tyr/Phe ratios were not different between male and female patients, and between patients with and without entacapone.
CONCLUSIONS: The low serum Tyr/Phe ratio differentiates PD from controls with sensitivity = 0.49, specificity = 1.00, positive predictive value = 1.00, and negative predictive value = 0.40.

Entities:  

Keywords:  Parkinson’s disease; biomarker; phenylalanine; tyrosine

Mesh:

Substances:

Year:  2016        PMID: 27061063     DOI: 10.3233/JPD-150736

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  6 in total

1.  Metabolomic Profiling of Aqueous Humor and Plasma in Primary Open Angle Glaucoma Patients Points Towards Novel Diagnostic and Therapeutic Strategy.

Authors:  Yizhen Tang; Yiqiong Pan; Yuhong Chen; Xiangmei Kong; Junyi Chen; Hengli Zhang; Guangxian Tang; Jihong Wu; Xinghuai Sun
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

2.  Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson's disease.

Authors:  Yi Zhang; Xiaoqin He; Yiwei Qian; Shaoqing Xu; Chengjun Mo; Zheng Yan; Xiaodong Yang; Qin Xiao
Journal:  NPJ Parkinsons Dis       Date:  2022-04-21

3.  Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.

Authors:  Can Cui; Yingying Han; Hongxia Li; Hongxiang Yu; Bei Zhang; Gang Li
Journal:  Front Cell Infect Microbiol       Date:  2022-08-10       Impact factor: 6.073

4.  Serum amino acid profile in patients with Parkinson's disease.

Authors:  Monika Figura; Katarzyna Kuśmierska; Ewelina Bucior; Stanisław Szlufik; Dariusz Koziorowski; Zygmunt Jamrozik; Piotr Janik
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

Review 5.  Brain Kynurenine and BH4 Pathways: Relevance to the Pathophysiology and Treatment of Inflammation-Driven Depressive Symptoms.

Authors:  Sylvie Vancassel; Lucile Capuron; Nathalie Castanon
Journal:  Front Neurosci       Date:  2018-07-24       Impact factor: 4.677

6.  The effects of combined intravenous cocaine and ethanol self-administration on the behavioral and amino acid profile of young adult rats.

Authors:  Alberto Marcos; Mario Moreno; Javier Orihuel; Marcos Ucha; Ana Mª de Paz; Alejandro Higuera-Matas; Roberto Capellán; Antonio L Crego; María-Rosa Martínez-Larrañaga; Emilio Ambrosio; Arturo Anadón
Journal:  PLoS One       Date:  2020-03-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.